$78,45
+$1,19(+1,54 %)
*Data last updated: 2026-06-19 08:33 (UTC+8)
As of 2026-06-19 08:33, Zoetis Inc (ZTS) is priced at $78,45, with a total market cap of $32,99B, a P/E ratio of 20,87, and a dividend yield of 2,61 %. Today, the stock price fluctuated between $76,47 and $79,47. The current price is 2,58 % above the day's low and 1,28 % below the day's high, with a trading volume of 8,55M. Over the past 52 weeks, ZTS has traded between $72,38 to $127,42, and the current price is -38,43 % away from the 52-week high.
ZTS Key Stats
Yesterday's Close$77,26
Market Cap$32,99B
Volumen8,55M
P/E Ratio20,87
Dividend Yield (TTM)2,61 %
Dividend Amount$0,53
Diluted EPS (TTM)6,26
Net Income (FY)$2,67B
Revenue (FY)$9,46B
Earnings Date2026-08-04
EPS Estimate1,85
Revenue Estimate$2,50B
Shares Outstanding427,09M
Beta (1Y)0.741
Ex-Dividend Date2026-07-20
Dividend Payment Date2026-09-01
About ZTS
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOKristin C. Peck
HeadquartersParsippany,NJ,US
Official Websitehttps://www.zoetis.com
Employees (FY)14,50K
Average Revenue (1Y)$652,89K
Net Income per Employee$184,34K
Zoetis Inc (ZTS) FAQ
What's the stock price of Zoetis Inc (ZTS) today?
x
Zoetis Inc (ZTS) is currently trading at $78,45, with a 24h change of +1,54 %. The 52-week trading range is $72,38–$127,42.
What are the 52-week high and low prices for Zoetis Inc (ZTS)?
x
What is the price-to-earnings (P/E) ratio of Zoetis Inc (ZTS)? What does it indicate?
x
What is the market cap of Zoetis Inc (ZTS)?
x
What is the most recent quarterly earnings per share (EPS) for Zoetis Inc (ZTS)?
x
Should you buy or sell Zoetis Inc (ZTS) now?
x
What factors can affect the stock price of Zoetis Inc (ZTS)?
x
How to buy Zoetis Inc (ZTS) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.






